These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 8402628

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.
    Dowsett M, Jones A, Johnston SR, Jacobs S, Trunet P, Smith IE.
    Clin Cancer Res; 1995 Dec; 1(12):1511-5. PubMed ID: 9815951
    [Abstract] [Full Text] [Related]

  • 4. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
    Goss PE, Clark RM, Ambus U, Weizel HA, Wadden NA, Crump M, Walde D, Tye LM, De Coster R, Bruynseels J.
    Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects of androgens on aromatase activity and 11C-vorozole binding in granulosa cells in vitro.
    Kirilovas D, Naessen T, Bergström M, Bonasera TA, Bergström-Pettermann E, Holte J, Carlström K, Simberg N, Långström B.
    Acta Obstet Gynecol Scand; 2003 Mar; 82(3):209-15. PubMed ID: 12694114
    [Abstract] [Full Text] [Related]

  • 10. Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor.
    Goss PE.
    Breast Cancer Res Treat; 1998 Mar; 49 Suppl 1():S59-65; discussion S73-7. PubMed ID: 9797019
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients.
    Geisler J, King N, Anker G, Ornati G, Di Salle E, Lønning PE, Dowsett M.
    Clin Cancer Res; 1998 Sep; 4(9):2089-93. PubMed ID: 9748124
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of peripheral aromatization in the male cynomolgus monkey by a novel nonsteroidal aromatase inhibitor (R 76713).
    Tuman RW, Morris DM, Wallace NH, Bowden CR.
    J Clin Endocrinol Metab; 1991 Apr; 72(4):755-60. PubMed ID: 2005200
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women.
    Iveson TJ, Smith IE, Ahern J, Smithers DA, Trunet PF, Dowsett M.
    J Clin Endocrinol Metab; 1993 Aug; 77(2):324-31. PubMed ID: 8345035
    [Abstract] [Full Text] [Related]

  • 17. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.
    Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A.
    Cancer; 1997 Feb 15; 79(4):730-9. PubMed ID: 9024711
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Practical synthesis of precursor of [N-methyl-11C]vorozole, an efficient PET tracer targeting aromatase in the brain.
    Takahashi K, Yamagishi G, Hiramatsu T, Hosoya A, Onoe K, Doi H, Nagata H, Wada Y, Onoe H, Watanabe Y, Hosoya T.
    Bioorg Med Chem; 2011 Feb 15; 19(4):1464-70. PubMed ID: 21273085
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.